Insulin resistance with impaired fasting glucose increases the risk of NAFLD — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Insulin resistance with impaired fasting glucose increases the risk of NAFLD
Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden
,
Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden
,
Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden;Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden
1 Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden
2 Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden
3 Department of Gastroenterology and Hepatology, Sk?ne University Hospital, Malm?, Sweden;Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Malm?, Sweden
Background: Our aim was to investigate the frequency of elevated liver enzymes and NAFLD in patients with known insulin resistance during 15 years of follow-up. Methods: Subjects with insulin resistance were identified from a population-based prospective cohort study in Sweden, Malm ? Diet and Cancer Study, conducted in 1991-1996. Inall, 285 non-diabetic subjects with insulin resistance established by HOMA-IR (homeostasis model assessment) were invited to do the liver function testing and if elevated, they should be further assessed by radiological examination of the liver, anthropometric measures and blood testing. Results: 165 subjects (57.9%) agreed to do the liver function testing. Of these, 25 subjects (15%) had elevated liver enzymes. After exclusion of other diseases, 5 of the remaining 21 subjects (23.8%) had radiological signs of steatosis. Liver steatosis significantly correlated with ALT (alanine aminotransferase) (p = 0.04), HOMA-IR (p = 0.00) and the metabolic syndrome (p = 0.03). 80% of the subjects with NAFLD had either developed type 2 diabetes mellitus or had impaired fasting glucose and 80% fulfilled the WHO-criteria for the metabolic syndrome, which were of significant differences to the group without NAFLD. Conclusion: The risk of developing elevated liver enzymes and NAFLD at long-term follow-up in insulin resistant subjects is not insignificant, but mainly associated with the simultaneous development of impaired fasting glucose, established diabetes mellitus and/ or the metabolic syndrome.
Angulo, P. (2002) Nonalcoholic fatty liver disease. New England Journal of Medicine, 346, 1221-1231. doi:10.1056/NEJMra011775
Sass, D.A., Chang, P. and Chopra, K.B. (2005) Nonalcoholic fatty liver disease: A clinical review. Digestive Diseases and Sciences, 50, 171-180. doi:10.1007/s10620-005-1267-z
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C. and Roudot-Thoraval, F. (2013) The burden of liver disease in Europe: A review of available epidemiological data. Journal of Hepatology, 58, 593-608. doi:10.1016/j.jhep.2012.12.005
Torres, D.M., Williams, C.D. and Harrison, S.A. (2012) Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 10, 837-858. doi:10.1016/j.cgh.2012.03.011
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37, 917-923. doi:10.1053/jhep.2003.50161
Balkau, B., Charles, M.A., Drivsholm, T., Borch-Johnsen, K., Wareham, N., Yudkin, J.S., et al. (2002) Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes & Metabolism, 28, 364-376.
Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The metabolic syndrome. Lancet, 365, 1415-1428. doi:10.1016/S0140-6736(05)66378-7
Hernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F.L., Guallar, E., et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology, 54, 1082-1090. doi:10.1002/hep.24452
Schwenzer, N.F., Springer, F., Schraml, C., Stefan, N., Machann, J. and Schick, F. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. Journal of Hepatology, 51, 433-445. doi:10.1016/j.jhep.2009.05.023
Schindhelm, R.K., Diamant, M., Dekker, J.M., Tushuizen, M.E., Teerlink, T. and Heine, R.J. (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/Metabolism: Research and Reviews, 22, 437-443. doi:10.1002/dmrr.666
Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 48, 792-798. doi:10.1002/hep.22429
Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A., et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37, 1286-1292. doi:10.1053/jhep.2003.50229
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 123, 134-140. doi:10.1053/gast.2002.34168
Caldwell, S.H. and Crespo, D.M. (2004) The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. Journal of Hepatology, 40, 578-584. doi:10.1016/j.jhep.2004.02.013
Brunt, E.M. and Tiniakos, D.G. (2010) Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenteroly, 16, 5286-5296. doi:10.3748/wjg.v16.i42.5286
Dam-Larsen, S., Franzmann, M., Andersen, I.B., Christoffersen, P., Jensen, L.B., Sorensen, T.I., et al. (2004) Long term prognosis of fatty liver: Risk of chronic liver disease and death. Gut, 53, 750-755. doi:10.1136/gut.2003.019984
Farrell, G.C. and Larter, C.Z. (2006) Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology, 43, S99-S112. doi:10.1002/hep.20973
Haque, M. and Sanyal, A.J. (2002) The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology, 16, 709-731. doi:10.1053/bega.2002.0325
Day, C.P. (2002) Pathogenesis of steatohepatitis. Best Practice & Research Clinical Gastroenterology, 16, 663-678. doi:10.1053/bega.2002.0333
Fracanzani, A.L., Valenti, L., Bugianesi, E., Vanni, E., Grieco, A., Miele, L., et al. (2011) Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 54, 1244-1249. doi:10.1016/j.jhep.2010.09.037
Eguchi, Y., Mizuta, T., Sumida, Y., Ishibashi, E., Kitajima, Y., Isoda, H., et al. (2011) The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. Journal of Gastroenterology, 46, 70-78. doi:10.1007/s00535-010-0340-3
Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Targher, G., et al. (1998) Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes, 47, 1643-1649. doi:10.2337/diabetes.47.10.1643
Hedblad, B., Nilsson, P., Engstrom, G., Berglund, G. and Janzon, L. (2002) Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabetic Medicine, 19, 470-475. doi:10.1046/j.1464-5491.2002.00719.x
Nilsson, P.M., Engstrom, G., Hedblad, B., Frystyk, J., Persson, M.M., Berglund, G., et al. (2006) Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arteriosclerosis, Thrombosis and Vascular Biology, 26, 2758-2762. doi:10.1161/01.ATV.0000249638.01416.4b
Mathiesen, U.L., Franzen, L.E., Fryden, A., Foberg, U. and Bodemar, G. (1999) The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scandinavian Journal of Gastroenterology, 34, 85-91. doi:10.1080/00365529950172880
Bugianesi, E., McCullough, A.J. and Marchesini, G. (2005) Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology, 42, 987-1000. doi:10.1002/hep.20920
Leclercq, I.A., Da Silva Morais, A., Schroyen, B., Van Hul, N. and Geerts, A. (2007) Insulin resistance in heaptocytes and sinusoidal liver cells: mechanisms and consequences. Journal of Hepatology, 47, 142-156. doi:10.1016/j.jhep.2007.04.002
Tilg, H. and Moschen, A.R. (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology & Metabolism, 19, 371-379. doi:10.1016/j.tem.2008.08.005
Wallace, T.M., Levy, J.C. and Matthews, D.R. (2004) Use and abuse of HOMA modeling. Diabetes Care, 27, 1487-1495. doi:10.2337/diacare.27.6.1487
Rhee, E.J., Lee, W.Y., Cho, Y.K., Kim, B.I. and Sung, K.C. (2011) Hyperinsulinemia and the development of nonalcoholic Fatty liver disease in nondiabetic adults. American Journal of Medicine, 124, 69-76. doi:10.1016/j.amjmed.2010.08.012
Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 44, 865-873. doi:10.1002/hep.21327